01 December 2005
The impact of rosiglitazone on heat tolerance in patients with Type 2 Diabetes.
Jerrold Petrofsky, Scott Lee, Maria Cuneo-LibaronaMed Sci Monit 2005; 11(12): CR562-569 :: ID: 438852
Abstract
Background: Diabetes is associated with reduced tolerance to heat. Theinsulin sensitizer rosiglitazone (RSG), administered for glycemic control, has a secondary effect inincreasing vascular endothelial function. The hypothesis to be tested was if administration of rosiglitazonewould increase heat tolerance in people with diabetes. Material/Methods: Thirty subjects with diabetesand thirty control subjects were examined. A subset of 21 subjects with diabetes had RSG administeredat 4 mg per day for a period of 1 year. At 2 weeks, 4 weeks, 3 months, 6 months, and 1 year post administration,measurements were taken to assess any potential impact of this drug on thermoregulation. Parameters measuredwere sweat rate, skin temperature, body core temperature, and skin blood flow. Results: Results of theseexperiments showed that subjects with diabetes at baseline had 1) sensory impairment, 2) sweat glandimpairment 3) high skin temperatures, 4) and low blood flow reduction during heat exposure, all leadingto higher core temperature compared to controls subjects. After administration of rosiglitazone for 1year significant improvements in thermoregulation were observed. Trends for improvement in thermoregulationwere observed close to that of age matched control subjects. Conclusions: Heat tolerance can be improvedin people with diabetes when taking the insulin sensitizer RSG for Glycemic control, probably due toincreased endothelial cell function.
Keywords: Body Temperature Regulation - drug effects, Diabetes Mellitus, Type 2 - physiopathology, Hot Temperature, Hypoglycemic Agents - pharmacology, Skin Temperature - drug effects, Thiazolidinediones - pharmacology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
11 Mar 2024 : Clinical Research
Enhancement of Frozen-Thawed Human Sperm Quality with Zinc as a Cryoprotective AdditiveMed Sci Monit In Press; DOI: 10.12659/MSM.942946
12 Mar 2024 : Database Analysis
Risk Factors of Age-Related Macular Degeneration in a Population-Based Study: Results from SHIP-TREND-1 (St...Med Sci Monit In Press; DOI: 10.12659/MSM.943140
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952